Molytica

Vision - Currently only AI, but working towards diagnostics and pharmaceuticals

Input Data

Statistics

72% progress from 0 to perfection in protein interaction prediction

Currently 86% Accuracy, beating world record

Why?

- Diagnostics
  - Detect cancer and alzheimer's early → save healthcare costs, take some savings as profits
- Pharmaceuticals
  - Complex disease hard to solve with single target drugs
  - Utilize AI to find multi target drugs, which are impossible to find manually
  - New therapeutic effects, solve currently unsolvable disease which are high demand
- AI Labs
  - Develop AI from the ground up tailored for molecule analysis to power the above

How?

- Diagnostics
  - Neural North and Swedish Government blood samples (in progress)
    - Representative data for all ethnicities
    - Thousands of data points
  - Epigenica AB
    - Analyze blood samples to create raw data potentially for cancer detection and methylation aging
  - Molytica AI Labs
    - Goal is to use transformer models to diagnose cancer and alzheimer's early
    - Potentially also classify the cancer subtype
- Pharmaceuticals
  - Use Molytica AI Labs to generate molecule proposals
  - Evaluate with world class pharmacologists
  - Patent molecules and license

Official Advisory Board

Nora Caroline Källersjö

- Only Swedish student accepted to Harvard 2020
- Studying Math with Highest Grades

Clas Sonesson

- Professional Pharmacologist and Chemist developing Parkinson's medication
  - Parkinson's = complex disease = relevant for our company (multi target drug identification)
- 20 Years of experience
- 50 M EUR in funding
- Clinical Trials Phase III in the US

Adam Wuilmart

- Cofounder of Y Combinator sponsored Bemlo
- Associate at Boston Consulting Group

Other Candidates

AlzeCure Pharma AB

- Top Pharmacologists in Alzheimer's (relevant for our company)
- 13 years of experience, spinoff from AstraZeneca

Epigenica AB

- Sponsored by European Union and Karolinska Institutet
- Advice and research availability regarding epigenetics

Team

Oliver

- Headhunted 6 times, sometimes by Y Combinator sponsored startups
- Highest Grades at KTH Institute of Technology
- Learned Advanced Object oriented programming in one week at age 13 (java)
- Former. head of Advanced Pharmaceutical Development at Andrei Chagin Lab, Karolinska Institutet/Gothenburg University
- Former IT Project Leader, We Know IT
- World class network within life science.

Sebastian

- Professional Asset management at Ruth Asset Management
- Pursuing Masters Degree in Statistics and Economics at Stockholm University

Our first desired Employee

Partihand

- Has already started learning about quantum chemistry and produced infrastructure for generating molecule data based on chemical and electronic properties of atoms that he is sharing with us
- Talented, very fast learner, very eager to move to Stockholm to innovate in this fast moving city.
- Communicative about results in a clear manner.

Our current limitation

Compute Power.

Time is spent training models. To improve innovation efficiency, more computational power and more man-power would help.

Our Innovation Philosophy

Best People, Few but talented

Incorporate Generative AI for faster prototyping

PRINCIPLE OF THE DAY

RECOGNIZE THAT IT IS FAR BETTER TO FIND A FEW SMART PEOPLE AND GIVE THEM THE BEST TECHNOLOGY THAN TO HAVE A GREATER NUMBER OF ORDINARY PEOPLE WHO ARE LESS WELL EQUIPPED.

@RAYDALIO

Partnerships

Neural North, Karolinska Hospital - Multimodal Dataprovider with exclusive access to large amount of data from hospitals in Sub-saharan Africa. They might expand to include Swedish data as well.

Rickard Sandberg Lab, **Karolinska Institute**, exclusive access to high quality data accumulated over years, crucial for high precision, multi target drug identification. Might be the only high quality provider of this sort in the world.

AlzeCure Pharma AB, **First North Nasdaq**, We are having meetings with them and discussing but no official partnership yet.

Epigenica AB/Simon Elsässer Lab, **SciLifeLab** World leader in high quality epigenetic analysis with standardised data. We are having meetings with this company but no official partnership yet.

Vision

Use the latest AI to create new medicines and diagnostic tools

Competition

Alphabet sponsored isomorphic labs

- They have not reached out to Rickard sandberg, or Epigenica, meaning they have not secured the world highest quality data or shown interest in it
- They do not have a working email on their website
- They have operated for 2 years without any interesting results

Judgement

- They lack the biological and pharmacological expertise necessary for innovation

Current Assets

- World leading Protein Interaction prediction model
  - Useful for finding new drug targets, hence enabling new medication alleys
- Potentially one of the world's most sophisticated Multi Target Drug Identification system
  - Under development, enables new category of medicines
- World class partnerships
- World talented people in our team, partnerships and advisory board
- Sophisticated, but easy to use, Data Handling Infrastructure for biomedical data, allowing easy to use interface for innovating with AI models.

Request

- 2 M EUR for 20 % of Molytica (AI Labs + Diagnostics + Pharmaceuticals)

Exit

- IPO in 3 years

Capital Usage

2 M EUR
Breakdown

Capital Usage Breakdown (%)

- Sales, Meetings, and… — 5,0%
- Patent Costs — 10,0%
- Legal Costs — 10,0%
- Medical Testing of P… — 20,0%
- Compute Power — 40,0%
- 2 Full Time AI Engin… — 15,0%

Contact us

- CEO
  - oliver@molytica.ai
- Investor Relations
  - sebastian@molytica.ai